Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.54 |
| ▸ | CA1 | P00915 | 5/20 | 0.54 |
| ▸ | CA2 | P00918 | 5/20 | 0.54 |
| ▸ | CA9 | Q16790 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TYMP | P19971 | 3/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | EGLN3 | Q9H6Z9 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9117495 | 0.89 | CA12 (0.50) | CA12CA1CA2CA9LMNA | |
| SCHEMBL28356736 | 0.88 | CA12 (0.49) | CA12CA1CA2CA9LMNA | |
| SCHEMBL28356435 | 0.88 | CA12 (0.49) | CA12CA1CA2CA9LMNA | |
| SCHEMBL25211225 | 0.88 | CA12 (0.49) | CA12CA1CA2CA9LMNA | |
| SCHEMBL28352617 | 0.88 | CA12 (0.49) | CA12CA1CA2CA9LMNA | |
| SCHEMBL4398512 | 0.86 | CA12 (0.56) | CA12CA1CA2CA9LMNA | |
| SCHEMBL20902568 | 0.86 | CA12 (0.52) | CA12CA1CA2CA9LMNA | |
| SCHEMBL16353277 | 0.86 | CA12 (0.52) | CA12CA1CA2CA9LMNA | |
| SCHEMBL16353283 | 0.86 | CA12 (0.52) | CA12CA1CA2CA9LMNA | |
| SCHEMBL11390072 | 0.84 | CA12 (0.64) | CA12CA1CA2CA9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240424011-A1 | COMBINATION THERAPY OF HYPOXIA-RESPONSIVE PRODRUG OF AN ANTICANCER DRUG AND RADIOTHERAPY, AND NOVEL HYPOXIA-RESPONSIVE PRODRUG | UNIVERSITY OF TSUKUBA (JP) | 2024-12-26 | — | — | US | disclosed |
| EP-4454646-A1 | COMBINATION THERAPY INVOLVING RADIOTHERAPY AND HYPOXIA-RESPONSIVE PRODRUG OF ANTICANCER DRUG, AND NOVEL HYPOXIA-RESPONSIVE PRODRUG | University of Tsukuba (JP) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023120331-A1 | COMBINATION THERAPY INVOLVING RADIOTHERAPY AND HYPOXIA-RESPONSIVE PRODRUG OF ANTICANCER DRUG, AND NOVEL HYPOXIA-RESPONSIVE PRODRUG | 国立大学法人筑波大学 | 2023-06-29 | — | — | WO | disclosed |
| EP-2816036-B1 | PRODRUG USING NITROIMIDAZOLE | UNIV TSUKUBA (JP) | 2019-04-17 | — | — | EP | disclosed |
| CN-107417672-A | One kind is based on 2,2 dimethyl 3（2 nitroimidazole bases）The hypoxemia activation prodrug of propionic acid | 华东师范大学 | 2017-12-01 | — | — | CN | disclosed |
| US-9655975-B2 | Prodrug using nitroimidazole | UNIVERSITY OF TSUKUBA (JP) | 2017-05-23 | — | — | US | disclosed |
| US-9655975-B2 | Prodrug using nitroimidazole | UNIVERSITY OF TSUKUBA (JP) | 2017-05-23 | — | — | US | disclosed |
| US-9655975-B2 | Prodrug using nitroimidazole | UNIVERSITY OF TSUKUBA (JP) | 2017-05-23 | — | — | US | disclosed |
| US-9655975-B2 | Prodrug using nitroimidazole | UNIVERSITY OF TSUKUBA (JP) | 2017-05-23 | — | — | US | disclosed |
| US-20140378673-A1 | PRODRUG USING NITROIMIDAZOLE | UNIVERSITY OF TSUKUBA (JP) | 2014-12-25 | — | — | US | disclosed |
| US-20140378673-A1 | PRODRUG USING NITROIMIDAZOLE | UNIVERSITY OF TSUKUBA (JP) | 2014-12-25 | — | — | US | disclosed |
| US-20140378673-A1 | PRODRUG USING NITROIMIDAZOLE | UNIVERSITY OF TSUKUBA (JP) | 2014-12-25 | — | — | US | disclosed |
| US-20140378673-A1 | PRODRUG USING NITROIMIDAZOLE | UNIVERSITY OF TSUKUBA (JP) | 2014-12-25 | — | — | US | disclosed |
| EP-2816036-A1 | PRODRUG USING NITROIMIDAZOLE | University of Tsukuba (JP) | 2014-12-24 | — | — | EP | disclosed |
| EP-2816036-A1 | PRODRUG USING NITROIMIDAZOLE | University of Tsukuba (JP) | 2014-12-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378673-A1 | PRODRUG USING NITROIMIDAZOLE | HIF1AN, HIF1A, PAICS | CA12 450/4885CA1 73/4885CA2 117/4885 |
| US-20240424011-A1 | COMBINATION THERAPY OF HYPOXIA-RESPONSIVE PRODRUG OF AN ANTICANCER DRUG AND RADIOTHERAPY, AND NOVEL HYPOXIA-RESPONSIVE PRODRUG | HIF1AN, HIF1A, PAICS | CA12 2205/4885CA1 2544/4885CA2 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.